Foghorn Therapeutics (FHTX) Invested Capital (2020 - 2025)
Historic Invested Capital for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$89.7 million.
- Foghorn Therapeutics' Invested Capital fell 21695.83% to -$89.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$89.7 million, marking a year-over-year decrease of 21695.83%. This contributed to the annual value of -$45.5 million for FY2024, which is 4101.83% up from last year.
- According to the latest figures from Q3 2025, Foghorn Therapeutics' Invested Capital is -$89.7 million, which was down 21695.83% from -$76.7 million recorded in Q2 2025.
- In the past 5 years, Foghorn Therapeutics' Invested Capital ranged from a high of $144.9 million in Q1 2021 and a low of -$97.5 million during Q1 2024
- In the last 5 years, Foghorn Therapeutics' Invested Capital had a median value of -$24.6 million in 2023 and averaged -$576421.1.
- In the last 5 years, Foghorn Therapeutics' Invested Capital soared by 24317.91% in 2021 and then plummeted by 6901964.29% in 2023.
- Over the past 5 years, Foghorn Therapeutics' Invested Capital (Quarter) stood at $96.9 million in 2021, then crashed by 99.88% to $112000.0 in 2022, then plummeted by 69019.64% to -$77.2 million in 2023, then soared by 41.02% to -$45.5 million in 2024, then tumbled by 96.93% to -$89.7 million in 2025.
- Its Invested Capital stands at -$89.7 million for Q3 2025, versus -$76.7 million for Q2 2025 and -$61.7 million for Q1 2025.